Contact Us
enptesit

LIMB SALVAGE OF DFUs USING ON101 TOPICAL CREAM: REAL-WORLD EVIDENCE

Methods
  • Study Type: Prospective observational study
  • Population: 59 patients with IDSA Grade 2 infected DFUs
  • Treatment Groups:

  • Treatment Duration: Up to 16 weeks
  • Concomitant Management: Etiology-specific interventions (e.g., vascular support, offloading)

 

Executive summary

This RWE study confirms that ON101 topical cream is an effective treatment option for high-risk iDFUs, both alone and as part of a combined advanced wound care strategy, as it:

  • Enhances granulation and epithelialization
  • Reduces amputation risk
  • Lowers overall clinical burden and treatment time

These real-world results reinforce ON101’s value as a critical addition to the DFU treatment algorithm.

Result
  • Product Usage: ＜2 tubes per patient (avg.)
  • Combo Group: In complex cases (e.g., tendon/bone exposure), ON101 + NPWT optimized the wound bed for grafting or closure within 2–3 weeks, reducing hospitalization needs
  • Safety: No AE reported

 

Pubblicazione del CongressoSAWC Fall 2025
Data di PubblicazioneSeptember 3rd, 2025
AutoriProf. Mohamed Sharkawy, MD
Informazioni sugli AutoriCairo University Hospital, Egypt
Poster Presentation

LIMB SALVAGE OF DFUs USING ON101 TOPICAL CREAM: REAL-WORLD EVIDENCE

Introduction

Diabetic foot ulcers (DFUs) are a serious and frequent complication of diabetes, particularly in patients with poor glycemic control, foot deformities, and infection. Infected DFUs (Wagner Grade 1–3) are notoriously difficult to manage and carry a high risk of amputation. ON101 is a topical medical device developed to support
the wound healing process in clinical settings. This prospective real-world study evaluated ON101’s effectiveness in limb salvage and wound healing among high-risk patients with infected diabetic foot ulcers (iDFUs).

Download
Back